Challenges in translating nanotechnology from research to clinical practice.

Nanotechnology has emerged as a promising frontier in the identification and treatment of skin cancer by offering innovative platforms for targeted drug administration, real-time imaging, and enhanced therapeutic efficacy. Though preclinical results are promising and scientific enthusiasm is rising, the shift of nanotechnological breakthroughs from research laboratories to clinical environments remains hampered. The main translational problems preventing the clinical acceptance of nanomedicine in skin cancer treatment are investigated in this chapter. It explores obstacles like manufacturing scalability, reproducibility, regulatory uncertainty, clinical trial design restrictions, financial limits, and intellectual property complexity. Moreover, the chapter describes strategic ways to get beyond these obstacles: multidisciplinary cooperation, regulatory harmonization, and the inclusion of digital technologies into development pipelines together with artificial intelligence (AI). This chapter seeks to give a complete knowledge of what it takes to propel nanotechnology beyond the bench and into pragmatic, patient-centred applications in oncology by closely analysing both the challenges and possible solutions.